Cabot (CBT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
27 Jan, 2026Executive summary
Annual meeting scheduled for March 12, 2026, to be held virtually; shareholders will vote on director elections, executive compensation, and auditor ratification.
Board recommends voting for all proposals, including the election of three directors, advisory approval of executive compensation, and ratification of Deloitte & Touche LLP as auditor.
Proxy materials distributed via internet to promote environmental responsibility; shareholders can request paper copies.
Forward-looking statements address business strategies, growth opportunities, and risk factors, with caution regarding uncertainties.
Voting matters and shareholder proposals
Shareholders will elect three directors for terms expiring in 2029, approve executive compensation in an advisory vote, and ratify the appointment of Deloitte & Touche LLP as independent auditor for fiscal 2026.
Board recommends voting for all three proposals.
Procedures for submitting shareholder proposals and director nominations for the 2027 meeting are outlined, with specific deadlines.
Board of directors and corporate governance
Board reduced from eleven to nine members after the meeting; all directors except the CEO are independent.
Board committees (Audit, Compensation, Governance, SHE & S) are fully independent and oversee key areas including risk, compensation, and sustainability.
Board diversity emphasized, with one-third women and one-third ethnically diverse members.
Board refreshment ongoing, with three new directors in the last four years.
Non-Executive Chair leads the board, with clear separation from CEO responsibilities.
Latest events from Cabot
- Adjusted EPS down 13% to $1.53; Battery Materials up 39%, Reinforcement Materials EBIT down 22%.CBT
Q1 20264 Feb 2026 - Q3 adjusted EPS up 35% year-over-year; FY2024 guidance raised on strong segment growth.CBT
Q3 20242 Feb 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.CBT
Proxy Filing27 Jan 2026 - 31% EPS growth, $265M returned to shareholders, and 2025 EPS guidance of $7.40–$7.80.CBT
Q4 202416 Jan 2026 - FY24 adjusted EPS guidance raised to $7.00–$7.10, driven by battery, E2C, and inkjet growth.CBT
Investor Day 202412 Jan 2026 - Adjusted EPS up 13% to $1.76; net income and cash flow drive strong shareholder returns.CBT
Q1 20259 Jan 2026 - Annual meeting to vote on directors, executive pay, new incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025 - Key votes include director elections, executive pay, incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025 - Q3 FY25 Adjusted EPS was $1.90, with mixed segment results and strong cash flow.CBT
Q3 202523 Nov 2025